Document is current
Any future updates will be listed below
-
Authors
Buynak, Robert
Cannon, Kevin
DeAtkine, David
Kirby, John
Usdan, Lisa https://orcid.org/0000-0002-5788-3938
Bhavsar, Amit https://orcid.org/0000-0002-5956-2003
Gérard, Catherine
Kuznetsova, Anastasia
Jayadev, Amulya
Amare, Hiwot https://orcid.org/0000-0003-2365-3963
Valenciano, Sofia https://orcid.org/0009-0007-9740-881X
Meyer, Nadia
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05559476 at ClinicalTrials.govDocuments that mention this clinical trial
Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65
https://doi.org/10.1007/s40121-024-00985-4
-
Funding
Funding for this research was provided by:
GSK
- License Information
-
More Information
Article History
Received: 1 February 2024
Accepted: 30 April 2024
First Online: 26 June 2024
Declarations
:
: Sofia Valenciano, Hiwot Amare, Amit Bhavsar, Catherine Gérard, Amulya Jayadev, Anastasia Kuznetsova, and Nadia Meyer are employees of GSK and may hold stock options. Robert Buynak received funding from GSK to conduct clinical research. David DeAtkine is a medical director at Central Research Assoc Inc. and receives payment as Principal Investigator for different studies. Kevin Cannon, John Kirby, and Lisa Usdan declare no conflicts of interest. AS01 is a trademark owned by or licensed to the GSK group of companies.
: This study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki and the principles of Good Clinical Practice, and was approved by all applicable regulatory agencies, investigational center ethics committees, or institutional review boards. The study protocol and amendments, the informed consent, and other relevant information were reviewed by a national, regional, or investigational center ethics committees, or institutional review boards.
